FOLH1 and neuroendocrine neoplasm: Retrospective studies on unselected real-world patients with mCRPC have shown comparable efficacy and safety of [177Lu]Lu-PSMA-617.12,20–22 Notably, the rate of FDG PET-CT use was not reported in these studies.12,20,21 Due to the observation of rare long-term hematological AEs in patients with neuroendocrine tumors after the use of 177Lutetium in peptide receptor radionuclide therapy (PRRT),23,24 a German study focused on [177Lu]Lu-PSMA-617 associated myelosuppression.